Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned
about
Real-world study of everolimus in advanced progressive neuroendocrine tumors.A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine TumorsManagement of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis.A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementDecoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase.Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.NETs: organ-related epigenetic derangements and potential clinical applications.Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?Pneumocystis pneumonia in everolimus therapy: An indistinguishable case from drug induced interstitial lung diseaseAre targeted therapies a consideration in poorly differentiated neuroendocrine tumors?Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index.Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
P2860
Q33417013-57390EE0-E22E-48A5-98B4-4CC1208192DBQ33432714-52AA4574-4FAC-423D-AECE-6AC9ED3B8D12Q36184629-B4BC4CEB-95A8-47A6-A808-F6719593D9A8Q36236672-8042F468-F3DE-41E7-8540-EF5AA4714B99Q36568335-26A32C92-7FAA-4029-B798-9AB646D296C4Q37282982-4EB0FD69-B0A0-4F95-8B0C-9734B941D547Q37302087-21A1D3B8-E426-45C1-A4E6-EDB005E184AAQ37634917-C20ACF7E-172D-4991-BE20-BE57BBEAF8FDQ38290097-90789BDC-0BE4-4FCC-AEDD-F73C7ECD8A19Q38658730-CF9C6E01-D6F9-4624-B93C-63DF50235F8DQ38738859-30891CB8-F14B-4A1F-B0C4-1A0D91ABA887Q38841735-A907D8FA-6C21-47B0-9DAE-78FE0DAD6D3CQ39168537-B3B78E01-9150-4A54-8BB3-842D99CC4D42Q40884345-F2DADC67-CC4E-4E5C-A50E-1E68DB9AAE31Q42910796-61F668CF-2967-41AD-A6A8-0FE359D91FB3Q45071563-97D5C3C2-D422-4967-863D-1DDD5102A8D5Q47677607-93783D6C-19DF-466C-BE8B-8B68CEC55B9CQ50700218-2859E3F6-A3D7-4A5C-8D5D-7C088A10BF29
P2860
Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeted therapies in neuroend ...... challenges and lessons learned
@en
type
label
Targeted therapies in neuroend ...... challenges and lessons learned
@en
prefLabel
Targeted therapies in neuroend ...... challenges and lessons learned
@en
P2093
P2860
P1433
P1476
Targeted therapies in neuroend ...... challenges and lessons learned
@en
P2093
Diane Reidy Lagunes
James C Yao
Matthew H Kulke
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0434
P577
2013-04-24T00:00:00Z